Company Overview and News
Stop missing out on important events!
Uscom Ltd (ASX:UCM) remains focused on cardiovascular and pulmonary medical devices, and is developing new non-invasive technologies to address the challenges of global disease and health care.
Uscom Ltd (ASX:UCM) has been awarded an additional European scientific research grant to fund the research and development of new digital pulmonary disease management technologies.
Uscom (ASX:UCM) has achieved its first ever cash flow positive quarter, with results for the Q3 2017 quarter demonstrating record cash receipts of $1.41 million.
The advisory group includes a number of leading Australian academics and entrepreneurs with high level China experience, and is the initiative of the New South Wales Health Minister, Jillian Skinner. The group will act to develop and guide New South Wales Health to engage with Chinese academics and entrepreneurs and to lead commercial and educational opportunities between Australia and China. Uscom is a Sydney based developer and manufacturer of advanced medical devices, specialising in cardiovascular and pulmonary monitoring.
USCOM Ltd (ASX:UCM) has received the European CE Mark for its Uscom SpiroSonic digital ultrasonic technology, allowing sale of the device in Europe.